<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01993849</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00028506</org_study_id>
    <nct_id>NCT01993849</nct_id>
  </id_info>
  <brief_title>Use of NAC in Fingernail Biting</brief_title>
  <official_title>A Randomized Placebo-controlled Trial of N-Acetylcysteine in Onychophagia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kevin Gray</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of South Carolina</source>
  <brief_summary>
    <textblock>
      To conduct a pilot randomized placebo-controlled feasibility trial of N-acetylcysteine (NAC)
      in onychophagia, preliminarily assessing the tolerability and effects of this pharmacotherapy
      on young adults who bite their fingernails. It is proposed that NAC will help decrease
      fingernail biting.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Feasibility of conducting a trial of NAC in fingernail biters.</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in rate of fingernail biting</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Craving for nail biting</measure>
    <time_frame>12 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Measurement of nail length</measure>
    <time_frame>12 weeks</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Onychophagia</condition>
  <arm_group>
    <arm_group_label>NAC</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Twice daily dosing for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Twice daily dosing for 8 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>N-Acetylcysteine (NAC)</intervention_name>
    <arm_group_label>NAC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1. Age 18-30 2. Fingernail biter for â‰¥5 years

        Exclusion Criteria:

          -  1. Any unstable major DSM-IV Axis I psychiatric disorder in the past month (e.g.,
             psychotic disorders, bipolar disorder, major depressive disorder) 2. Current substance
             dependence in the past month 3. Current unstable major medical disorder or medical
             condition in the past 6 months (e.g., renal impairment) 4. Current pregnancy or
             breastfeeding 5. Current seizure disorder or asthma, due to possible elevated risk for
             adverse effects with NAC in individuals with these conditions 6. Known
             hypersensitivity to NAC 7. Use of carbamazepine or nitroglycerin (or any other
             medication deemed to be hazardous if taken with NAC) within 14 days of study
             participation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 24, 2013</study_first_submitted>
  <study_first_submitted_qc>November 19, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 25, 2013</study_first_posted>
  <last_update_submitted>March 7, 2016</last_update_submitted>
  <last_update_submitted_qc>March 7, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 8, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of South Carolina</investigator_affiliation>
    <investigator_full_name>Kevin Gray</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Anxiety</keyword>
  <keyword>Impulse control</keyword>
  <keyword>Depression</keyword>
  <keyword>ADHD</keyword>
  <keyword>Fingernail Biting</keyword>
  <keyword>N-Acetylcysteine</keyword>
  <keyword>NAC</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetylcysteine</mesh_term>
    <mesh_term>N-monoacetylcystine</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>April 24, 2018</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

